Amarin Corporation plc (AMRN)
Symbol Info
Listed Symbol AMRN
Name Amarin Corporation plc
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $229,215,000
Latest Fiscal EPS $-0.39
Price Info
21 Day Moving Average $15.2971
21 Day EMA $15.492980
50 Day Moving Average $15.5122
50 Day EMA $15.954610
200 Day EMA $16.281220
200 Day Moving Average 17.722650
52 Week High $23.91
52 Week Low $11.78
52 Week Change $-19.791100
Alpha 0.094461
Beta 1.1537
Standard Deviation 0.558304
R2 0.005036
Periods 60
Share Information
10 Day Average Volume 4,409,143
20 Day Average Volume 5,470,961
30 Day Average Volume 5,441,685
50 Day Average Volume 6,655,432
Outstanding Shares 357,214,478
Float Shares 354,227,637
Percent Float 99.16%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 405
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 12,089,907
Institute Holdings Percent 50.900000
Institute Sold Previous 3 Months 12,637,154
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 19
Insider Holdings Percent 0.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,986,841
Price Change
7 Day Price Change $0.9099989
7 Day Percent Change 5.98%
21 Day Price Change $0.9799995
21 Day Percent Change 6.47%
30 Day Price Change $-0.8000011
30 Day Percent Change -4.73%
Month To Date Price Change $0.9700
Month To Date Percent 6.40%
90 Day Price Change $-2.770001
90 Day Percent Change -14.66%
Quarter To Date $0.969999
Quarter To Date Percent 6.40%
180 Day Price Change $-1.93
180 Day Percent Change -10.69%
200 Day Price Change $-3.990002
200 Day Percent Change -19.83%
Year To Date $2.520000
Year To Date Percent 18.52%
Profile
Description Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa. The firm has Development and Commercialization of Vascepa operating segment. It mainly operates in the United States.
Details
Issue Type CS
Market Cap $5,761,869,530
Sec Type DR
Auditor Ernst & Young LLP
Total Shares Outstanding 357,214,478
CEO John F. Thero
Employees 530
Last Audit UQ
Classification
CIK 0000897448
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address Upper Pembroke Street 28-32
2 Pembroke House
Dublin, 2
Website http://www.amarincorp.com
Facisimile
Telephone +353 16699020
Email investor.relations@amarincorp.com
Key Ratios
Profitability
EBIT Margin -24.9
EBITDA Margin -24.7
Pre-Tax Profit Margin -78.7
Profit Margin Cont -23.83
Gross Margin 76.90
Profit Margin TOT -23.83
Income Statements
Revenue $251,400,000
Revenue Per Share $0.7038
Revenue 3 Years $24.66
Revenue 5 Years $38.35
Valuation Measures
PE Ratio -
Enterprise Value $5,292,222,486
Price To Sales 22.919128
Price To Free Cash -91.2
PE High Last 5 Years -
Price To Book 39.6
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 42.0
Financial Strength
Total Debt To Equity 0.6
Int Coverage -9.8
Current Ratio 2.0
Leverage Ratio 2.1
Quick Ratio 1.7
Long Term Debt To Capital 0.17
Assets
Receivables Turnover 1.7
Invoice Turnover 1.60
Assets Turnover 0.40
Management Effectiveness
Return Assets -28.41
Return On Equity -300.4
Return On Capital -63.77
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AMRN
Amarin
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.